Study on an AML-associated A338V mutation in GPR183 published in JACS
Here, we combined bioluminescence/fluorescence resonance energy transfer, bioluminescence- and fluorescence-based assays as well as migration experiments, with molecular dynamics simulations and allosteric communication networks to define the structura... (Link)
Read more
Nature Communications paper on a novel GPR183 inverse agonist and receptor activation switch
GPR183 is a chemotactic GPCR involved in immune cell migration. Using AI-driven virtual screening and biophysical assays, we identify inverse agonists. From 70 compounds and a subsequent hit expansion, compound 78 emerges as a potent inhibitor of const... (Link)
Read more
Pre-print on a AML-associated mutation in GPR183
We demonstrate that the A338V substitution selectively alters C-terminal structural dynamics, impairing GRK2 and β-arrestin2 recruitment while preserving G protein activation. Link to the study: https://www.biorxiv.org/content/10.64898/2026.03.30.7153...
Read more
GPR61 in severe obesity - publication in Molecular Pharmacology
We have identified and characterize mutants of GPR61 found in samples from severe obese individuals. Please see here: https://molpharm.aspetjournals.org/article/S0026-895X(25)15286-3/fulltext
Publication on GPCRs in blood cancers
In the paper, we analyze GPCR expression data in Acute Lymphoblastic Leukaemia, focusing on orphan GPCRs. Addtionally, we discuss receptors implicated or at least highly expressed in other forms of hematological cancers. Please see https://pubs.acs.org...
Read more